UK: A recent systematic review published in Clinical Rheumatology has investigated the potential of botulinum toxin (BTX) as ...

“BTX-A is a therapeutic method shown to solve a significant problem for patients with [Raynaud’s phenomenon] secondary to scleroderma; however, the evidence published so far is not sufficient ...

It’s normal to be colder in the winter — but what’s not normal is extremities growing so cold that they go numb and turn ...

Twenty-four patients with Raynaud's phenomenon and scleroderma were randomly assigned to receive finger temperature biofeedback, frontalis EMG biofeedback, or autogenic training. Only those ...

This condition is often associated with systemic sclerosis (scleroderma), an autoimmune disease that causes skin and blood vessel changes. Traditional treatments for Raynaud's phenomenon have had ...

Scleroderma is an autoimmune connective ... Some examples of external stimuli are cold (in the case of Raynaud's phenomenon), toxic substances, such as organic solvents and silica dust, and ...

Cutaneous scleroderma: Usually only the skin is affected. However, muscles and joints can also be affected. Almost all patients have Raynaud's phenomenon. • Systemic sclerosis: Systemic sclerosis can ...

Professor Christopher Denton discusses key aspects of the 2024 British Society for Rheumatology guideline on managing systemic sclerosis.

The most prominent hallmarks of disease were Raynaud's phenomenon (96.3%), antinuclear antibodies (93.4%) and a typical capillaroscopic pattern (90.9%). Scleroderma was more common on fingers and ...